       Document 0127
 DOCN  M9640127
 TI    Role of zidovudine antiretroviral therapy in the pathogenesis of
       acquired immunodeficiency syndrome-related lymphoma.
 DT    9604
 AU    Levine AM; Bernstein L; Sullivan-Halley J; Shibata D; Mahterian SB;
       Nathwani BN; Department of Internal Medicine, University of Southern;
       California, School of Medicine, Los Angeles 90033, USA.
 SO    Blood. 1995 Dec 15;86(12):4612-6. Unique Identifier : AIDSLINE
       MED/96127807
 AB    The role of zidovudine and other antiretroviral agents in the
       pathogenesis of acquired immunodeficiency syndrome (AIDS)-related
       lymphomas has been somewhat controversial. In an attempt to elucidate
       the precise role of antiretroviral agents in the subsequent development
       of AIDS-related lymphoma, we performed a population-based, case-control
       study of human immunodeficiency virus (HIV)-seropositive patients with
       intermediate- or high-grade lymphoma in Los Angeles County, California,
       in which information regarding use of antiretroviral medications was
       ascertained. Diagnostic biopsy material was reviewed to confirm
       intermediate-or high-grade lymphoma. A structured interview, conducted
       with all cases and controls, included information about use of
       zidovudine and other antiretroviral agents. A total of 112 HIV-infected
       homosexual/bisexual men with lymphoma were matched to 112
       homosexual/bisexual men with asymptomatic HIV infection; 49 of the
       lymphoma cases were also matched to 49 additional controls with AIDS, as
       defined by conditions other than lymphoma. Positive histories of
       zidovudine use were reported by 44 (39%) lymphoma cases, 24 (21%)
       asymptomatic HIV controls, and 21 (42%) AIDS controls. The average
       duration of zidovudine use up to 12 months before lymphoma diagnosis was
       19.0 +/- 13.0 months (mean +/- SD) for the lymphoma cases, 12.6 +/- 10.5
       months for the asymptomatic controls, and 11.0 +/- 7.1 months for the
       AIDS controls. When comparing the 49 HIV-positive lymphoma cases with
       their 49 matched AIDS controls, all of whom were diagnosed with AIDS
       during the same time period, the matched relative odds of lymphoma
       associated with prior use of zidovudine was 0.43 (95% confidence
       interval [CI] = 0.17 to 1.12). In comparing all 112 lymphoma cases with
       49 AIDS controls, the unmatched relative odds of lymphoma associated
       with zidovudine use was 0.93 (95% confidence interval = 0.47 to 1.83).
       One lymphoma case and no AIDS control cases had a history of didanosine
       use; no lymphoma case or AIDS control cases had taken zalcitabine. We
       conclude that zidovudine is not associated with an increased risk of
       development of lymphoma among HIV-infected homosexual or bisexual men.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY  Adult  Aged  Antiviral
       Agents/*ADVERSE EFFECTS/THERAPEUTIC USE  Bisexuality  Case-Control
       Studies  Ethnic Groups  Homosexuality, Male  Human  Interviews  Los
       Angeles/EPIDEMIOLOGY  Lymphoma, AIDS-Related/*CHEMICALLY
       INDUCED/EPIDEMIOLOGY  Lymphoma, High-Grade/CHEMICALLY
       INDUCED/EPIDEMIOLOGY  Lymphoma, Intermediate-Grade/CHEMICALLY
       INDUCED/EPIDEMIOLOGY  Lymphoma, Non-Hodgkin's/*CHEMICALLY
       INDUCED/EPIDEMIOLOGY  Male  Middle Age  Odds Ratio  Risk Factors
       Support, U.S. Gov't, P.H.S.  Zidovudine/*ADVERSE EFFECTS/THERAPEUTIC USE
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

